Founder and BOD Member: A clinical stage company developing a phase 2 clinical agent, Q-122, a safe, orally available drug for controlling hot flashes in women with breast cancer and in post-menopausal women
BOD Member: A CNS drug discovery company whose lead asset is NP10679, an orally available, pH-sensitive, non-opioid antagonist of GluN2B-containing NMDA receptors that has finished a Phase 1 clinical trial. NP10679 is being developed as a possible treatment for perioperative pain and stroke.
PharmassetFounder and SAB Member: Pharmasset, a company Dr. Liotta co-founded developed sofosbuvir (Sovaldi), the breakthrough drug, which in many cases, provides a cure for hepatitis C infection (HCV). Pharmasset was acquired by Gilead Sciences in 2012 for $11.2 billion.
Triangle PharmaceuticalsSAB Member: Triangle Pharmaceuticals oversaw the development of emtricitabine through its Phase 3 clinical trials. In 2002 Triangle was acquired by Gilead Sciences who managed the final FDA approval of emtricitabine and now sells it as a component of several important HIV therapies including Truvada, Atripla, Complera, Biktarvy, Genvoya Odefsey, Descovy and Stribild.
MetastatixFounder, BOD and SAB Member: Metastatix oversaw the development of MSX-122 through two Phase 1 clinical trials (a healthy volunteer trial and a solid tumor trial for cancer patients who had failed all other therapies). It subsequently closed and MSX-122 was returned to Emory. Emory later licensed MSX-122 to Que Oncology who renamed it Q-122.
FOB SynthesisFounder and SAB Member: An antibacterial drug discovery focused on the development of novel classes of carbapenem antibiotics that are potential treatments for several Gram-positive and Gram-negative bacterial infections.
iThemba PharmaceuticalsFounder, BOD and SAB Member: iThemba is the Zulu word for hope. iThemba Pharmaceuticals was established to manufacture generic drugs using cost-effective, continuous flow methodologies. Although it is now closed, in its seven years of existence iThemba helped to train many of the emerging leaders in South Africa’s biopharmaceutical sector.